Protocol
11-191
Full Title
Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients with Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Purpose
Gemcitabine and cisplatin are standard drugs used to treat urothelial cancers (those of the bladder, ureters, urethra, and kidney). Not all patients can tolerate cisplatin, however, and they may receive gemcitabine and carboplatin.
The purpose of this study is to assess the safety and effectiveness of gemcitabine and pazopanib in patients with advanced urothelial cancers who have not yet received chemotherapy (“chemotherapy naive”) and are not candidates for cisplatin-based therapy. Pazopanib, which is approved for the treatment of renal cell carcinoma (a form of kidney cancer) interferes with cancer cell growth and reduces the growth of new blood vessels tumors need to grow and spread. Pazopanib is taken orally (by mouth), while gemcitabine is given intravenously (by vein).
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic urothelial cancer and not be candidates for cisplatin-based therapy.
- Patients may not have received prior chemotherapy for the urothelial cancer.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Dean Bajorin at 646-422-4333.
Disease(s)
Bladder Cancer
Kidney Cancer
Locations
ClinicalTrials.gov
Related Diseases
